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Analysis of C-MYC Function in Normal Cells
via Conditional Gene-Targeted Mutation
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or activity of cell cycle-specific genes (Zornig and Evan,
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CD95 or CD95 ligand. We discuss these findings with supported by ability of dominant-negative c-myc alleles
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sis in fibroblast and myeloid cell lines (Askew et al., c-Mycfl/fl MEFs infected with a control retrovirus (z200
hr for D/D versus 20 hr for fl/fl) (Figures 1C and 1E). We1991; Evan et al., 1992; Thompson, 1998), a process
apparently effected downstream from surface CD95 also observed a more significant accumulation of cells
in G0/G1 stage of the cell cycle and a reciprocal de-(Fas)/CD95L (FasL) interactions (Hueber et al., 1997).
Similarly, antigen receptor cross-linking in T cell hybrid- crease of cells in S phase (Figure 1D). Transduction of
c-MycD/D MEFs with a c-Myc encoding retrovirus re-omas induces apoptosis in a process that relies on in-
duction of CD95 and CD95L via a c-Myc-dependent stored significant growth and reduced the doubling time
to z35 hr but not to wild-type levels consistent with thepathway (Brunner et al., 1995; Ju et al., 1995; Dhein et
al., 1995; Genestier et al., 1999). In murine and human growth inhibitory effects of Cre-GFP expression alone
(Figures 1C, 1D, and 1E).B cell lymphoma lines, apoptosis induced via surface
IgM-cross-linking correlates with downregulation of To further characterize these cell cycle defects, we
employed Western blotting to assay the c-Myc-deficientc-myc expression (Fischer et al., 1994; Kaptein et al.,
1996; Wu et al., 1996, 1999; Sonenshein, 1997). To- MEFs for the status of several known cell cycle regula-
tors. As expected, the c-MycD/D MEFs lacked significantgether, these findings illustrate that the complex interre-
lationship of c-Myc and apoptosis is influenced by the levels of c-Myc relative to controls (Figure 1F, left). Hy-
perphosphorylation of Rb (Lee et al., 1987) is a correlatetype of apoptotic stimulus, growth factor milieu, and cell
type, among other parameters. of entry into the S phase. Accordingly, c-MycD/D MEFs
also showed decreased levels of hyperphosphorylatedGermline inactivation of c-myc results in multiple ab-
normalities and precipitates embryonic lethality circa Rb (Figure 1F, left), in conjunction with significantly
higher levels of p27 protein relative to control MEFsday 9–10 (Davis et al., 1993). The early lethality of
c-Myc-deficient mice has hampered the study of c-Myc (Figure 1F, left). In contrast, expression of Cre in wt
MEFs did not lead to a decrease in expression of Mycfunction in cell types such as normal mature lympho-
cytes. To overcome these limitations, we now report a (data not shown) or an accumulation of p27, suggesting
that Cre and Myc affect proliferation via different mecha-cre-loxp-based strategy (Thomas and Capecchi, 1987;
Gu et al., 1993) that allows somatic inactivation of the nisms (Figure 1F, right). Therefore, specific deletion of
c-myc in fibroblasts results in extended doubling timec-myc gene in diverse cell types. We have used this
approach to study c-Myc function in cultured primary and impaired G1 exit in association with upregulation
of the p27 cell cycle inhibitor.MEFs and in B lineage cells in vivo. In addition, these
studies have revealed insights into potential limitations
of current versions of the LoxP/Cre technology for gen- c-myc Inactivation in B Lymphocytes In Vivo
erating conditional gene inactivation. The generation of conditionally targeted mice, in which
the c-myc gene has been floxed, allows evaluation of
Results c-myc function in specific tissues in vivo by breeding
with mice carrying a tissue-specific cre recombinase
Generation of Conditional c-mycfl/fl Mice gene. To achieve B lineage cell-specific c-myc inactiva-
To facilitate in vivo analysis of c-myc function in differen- tion, mice heterozygous for the floxed allele (c-myc1/fl
tiated cells, we employed gene targeting (Thomas and mice) were bred with CD19cre “knockin” (CD19cre/1)
Capecchi, 1987; Gu et al., 1993) to imbed loxp sites in the mice (Rickert et al., 1997) and progeny bred to yield
mouse germline c-myc locus (designated fl, flox allele) homozygous c-mycfl/fl ; CD19cre /1 mice (c-mycfl/fl ; CD19cre)
(Figure 1A). Mice homozygous for this mutation (c-mycfl/fl) or heterozygous c-myc1; CD19cre/1 mice (c-myc1/fl;
show no obvious abnormalities, consistent with normal ex- CD19cre). Cre expression in CD19cre knockin mice oc-
pression and function of the floxed allele throughout devel- curs specifically in B lineage cells throughout their de-
opment (data not shown). Recombination between the two velopment and has been shown to lead to substantial
loxP sites mediated by the Cre recombinase leads to B lineage-specific deletion of floxed sequences (Rickert
the complete inactivation of the c-myc gene via deletion et al., 1997) (Figure 2A).
of exons 2 and 3 (Figure 1A). FACS analysis of bone marrow, lymph node, and
splenic B cell populations based on B220 and IgM ex-
pression was performed to analyze the effect of c-mycInactivation of c-Myc in Normal Fibroblasts
To assess the impact of c-Myc deficiency in normal deletion on these populations. Reduced numbers (z2-
to 3-fold in spleen) of IgM1 B lineage cells were observedcells, we first generated 13.5 day MEFs from homozy-
gous c-mycfl/fl mice and then deleted the c-myc gene in all analyzed c-mycfl/fl ; CD19cre mice, as compared to
c-myc1/fl ; CD19cre mice or wild-type mice (Figure 2B).from these cells in vitro via Cre-mediated recombination,
following infection with a retrovirus carrying a Cre-GFP The inability of Cre expression to effect obvious changes
in the number of splenic B cells of c-myc1/fl ; CD19cre micefusion protein (Figure 1B). Expression of the Cre-GFP
fusion protein in wt MEFs resulted in a 18%–35% de- by comparison to wild-type mice that do not express Cre
suggests that Cre does not of its own accord signifi-crease in proliferation over 6 days in multiple experi-
ments (Figures 1C and 1E). A corresponding increase cantly affect B cell development or numbers. Southern
blot analyses of purified c-mycfl/fl ; CD19cre splenic B cellsin accumulation of cells in G0/G1 and decrease in S
phase was also observed (Figure 1D). However, com- showed that z60%–70% of the floxed c-myc genes
were typically deleted, indicating that many c-mycfl/fl ;plete and acute deletion of c-myc in MEFs resulted in
a much more marked extension of the doubling time CD19cre splenic B cells must have deleted c-myc on both
floxed alleles (Figures 2A and 2C, D allele; also seeand reduction of the rate of proliferation in comparison
to wt MEFs infected with the Cre-GFP retrovirus or below). In contrast, mature B cells from spleens of
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Figure 1. Deletion of c-myc from Mouse Embryonic Fibroblasts
(A) c-myc genomic locus, targeting construct and in vitro Cre deletion of the selectable marker neomicin. In vitro deletion of the neo gene
results in c-myc locus flanked by 2 loxp sites (fl, flox allele).
(B) In vitro Cre-mediated deletion of c-myc in MEFs. Southern blot analysis of DNA from two independent lines of MEFs before (-) and after
infection with GFP-Cre retrovirus. After infection, GFP-positive cells were sorted by FACS. As a control, a retroviral vector expressing GFP
only was used to infect c-mycfl/fl fibroblasts. c-myc flox allele (fl, flox), c-myc deleted allele (D). DNA was digested with EcoRI and hybridized
with probe I (A).
(C) Growth curve of wt, c-mycfl/fl, and c-mycD/D MEFs. Wt MEFs were infected either with Cre-GFP (wt 1 Cre) or control GFP retrovirus (wt 1
GFP). c–myc-deficient (c-mycD/D) MEFs, obtained as described in (B), or c-mycfl/fl MEFs were infected with a Myc expressing retrovirus
(c-mycfl/fl 1 Myc, and c-mycD/D 1 Myc). Four independent experiments are shown. Each experiment represents independent MEF lines. MEFs
were harvested and plated at 2 3 105/10 cm dish. Duplicate plates were counted at the time points shown.
(D) Cell cycle analysis of c-Myc-deficient MEFs (c-mycD/D). Cells were cultured for 48 hr and stained with Propidium iodide for DNA content
and analyzed by FACS. Profile shown is representative of two independent experiments.
(E) Proliferation rates of MEF lines generated as in (A). Proliferation was determined using a WST-1 cleavage assay (Boehringer Mannheim).
Results shown are the average of two independent experiments performed in triplicate.
(F) Western blot analysis on c-myc deleted (c-mycD/D) and nondeleted c-mycfl/fl MEFs, and of wt MEFs infected with Cre or GFP expressing
retrovirus. The same amount of protein extract was used from all MEF lines. Immunoblot shown is representative of two independent
experiments. Rb, retinoblastoma protein; hypo, hypophosphorylated; and hyper, hyperphosphorylated.
c-myc1/fl ; CD19cre control mice showed nearly 100% lymphocytes within the same isogenic population in
culture.deletion of the single floxed allele, resulting in an equi-
molar ratio of wt and D alleles (Figure 2C). The continu-
ous CD19-cre expression (Rickert et al., 1997) and sub- Impaired Mitogenic Response of c-Myc
sequent deletion of floxed c-myc alleles throughout Null B Lymphocytes
development hampers an assessment of c-myc function To assess the capacity of mature B cells from c-mycfl/fl ;
in early development in vivo. However, the generation CD19cre mice to respond to a mitogenic stimulus, purified
of splenic B cell populations that are mosaic for cells B2201 spleen cells were stimulated with anti-CD40 anti-
with both c-myc alleles deleted and cells with intact body and interleukin 4 (IL-4) at various times. Following
c-myc alleles provides a unique opportunity to compare treatment, Southern blotting of DNA from the treated
c-mycfl/fl ; CD19cre population revealed a gradual loss ofthe behavior of deleted (D/D) and nondeleted (fl/fl) B
Immunity
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Figure 2. Deletion of c-myc from B Cells In Vivo
(A) Specific c-myc deletion in B lymphocytes in vivo. Southern blot of DNA from different organs of c-mycfl/fl; CD19cre and thymus of c-myc1/fl;
CD19cre mice.
(B) Number of B and T cells in the spleens of wt, heterozygous c-myc1/fl ; CD19cre mice, and homozygous c-mycfl/fl ; CD19cre 3- to 4-week-old
mice. The average of three mice of each genotype is shown.
(C) Southern blot of sorted mature B cells from spleen of a c-myc1/1 ; CD19cre or a heterozygous c-myc1/fl ; CD19cre mouse and a pool of 3–4
homozygous c-mycfl/fl ; CD19cre mice at 0 24, 48, 72, and 96 hr after activation with anti-CD40 antibody and interleukin 4. Each panel is
representative of two experiments with identical results. DNAs were processed as Figure 1B. c-myc flox allele (fl).
(D) Thymidine incorporation upon anti-CD40 plus IL-4 stimulation of purified B cells from wt mice (no Cre expression) or heterozygous
c-myc1/fl ; CD19cre and homozygous c-mycfl/fl ; CD19cre mice that express Cre (upper panels and lower left panel) and homozygous c-mycfl/fl
mice that do not express Cre (lower right panel).
(E) c-myc Southern blot of purified wt and heterozygous c-mycfl/1 ; CD19cre B cells indicating that Cre expression does not inhibit proliferation
of c-mycfl/1 B cells. Purified mature wt and heterozygous B cells were mixed at 1:1 ratio and activated with anti-CD40 and IL-4 for the indicated
times. No enrichment was observed for either wt or deleted (D) band after 3 days of culture. Experiment shown is representative of two
independent experiments.
the deleted (D) alleles over time (Figure 2C, left panel). of cells with nondeleted (flox) c-myc alleles relative to
those with deleted alleles (D). Furthermore, the nearlyBy 96 hr after activation, the intensity of the band corre-
sponding to deleted alleles (D) was greatly diminished complete outgrowth of flox/flox cells also indicates that
the majority of c-mycfl/fl ; CD19cre cells expressing Crerelative to that of the band corresponding to the floxed
alleles (fl) (Figure 2C, right panel; compare D versus fl experience deletion of both floxed c-myc alleles.
To further characterize the responses of c-Myc-defi-allele). Mixing and 3H-thymidine incorporation experi-
ments indicated that splenic B cells from c-myc1/fl; cient B cells to activating agents, anti-CD40 plus IL-
4-treated c-mycfl/fl ; CD19cre, c-myc1/fl ; CD19cre, and wtCD19cre and wt control mice proliferated equally well in
response to this treatment, again demonstrating that splenic B cell populations were assayed by FACS for
forward and side scatter before and after treatment.Cre expression has no obvious detrimental effects on
B cell proliferation (Figures 2D and 2E). Therefore, the Freshly isolated splenic B lymphocytes of all three geno-
types fall predominantly into the characteristic nonacti-observed loss of deleted alleles (D) from the c-mycfl/fl;
CD19cre B cell populations following anti-CD40/IL-4 vated population based on forward and side scatter
(Gate R; Figure 3A, 0 hr) (Iritani and Eisenman, 1999).treatment can be ascribed to the preferential expansion
Conditional Deletion of c-Myc in B Cells
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Figure 3. Failure of c-Myc-Deficient B Cells
to Undergo Activation
(A) Forward versus side scatter analysis of
sorted mature B cells from spleen of a wt, a
heterozygous c-myc1/fl ; CD19cre and a pool
of 3–4 homozygous c-mycfl/fl ; CD19cre mice
(3–4 weeks old). Cells were activated with
anti-CD40 antibody and interleukin 4, and
FACS analysis was performed at 0 and 48 hr.
(B) c-myc-deficient B cells (D/D) are localized
in gate (R). Activated B cells were purified
from c-mycfl/fl ; CD19cre mice, and PCR analy-
sis was performed to detect the presence of
the deleted (D-PCR) and nondeleted (fl-PCR)
c-myc gene. After 48 hr after activation with
anti-CD40 antibody, and interleukin 4 cells
were sorted by FACS using gates R or A as
indicated in (A) before performing PCR.
Mouse embryonic fibroblasts, DNA from un-
deleted (MEF fl), or deleted (MEF D) and am-
plification of the constant region of IgM
served as controls.
Following 48 hr of treatment, the majority of c-myc1/fl ; crease in CD95 or CD95L levels as compared 10-fold
greater levels of induction observed for fl/fl cells (FigureCD19cre and wt B cells show a forward/side scatter pro-
file typical of activation (gate A); whereas a significant 4B). In accord with these expression patterns, our pre-
liminary analyses demonstrated that the anti-CD40 plusnumber of B cells from c-mycfl/fl ; CD19cre mice remain
in a nonactivated (gate R) profile (Figure 3A and legend). IL-4-treated c-MycD/D B cells were more resistant to anti-
CD95-induced death than the activated c-Mycfl/fl cellsTo determine which cells underwent Cre-mediated
c-myc deletion in treated c-mycfl/fl ; CD19cre B cell popula- (data not shown). Together, our findings indicate that
c-Myc-deficient B cells, upon anti-CD40 and IL-4 treat-tions, we employed PCR to assay for the relative content
of fl and D c-myc alleles in DNA of B cells from gate R ment, are competent to execute the early signaling steps
of activation but fail to complete all of the downstreamor A (Figure 3A and legend). These analyses showed
that the majority of the c-mycfl/fl ; CD19cre B cells in gate steps associated with normal activation.
R (80%–85%) correspond to c-myc-deleted (null) B cells
(D-PCR), while nondeleted cells (fl-PCR) reside predomi- c-Myc-Deficient B Lymphocytes Accumulate
at the G0/G1 Stage of the Cell Cyclenantly within gate A. The presence of some D alleles in
gate A cells is most likely due to contamination during To further elucidate the proliferation defect of c-Myc-
deficient B cells relative to control B cells following anti-flow sorting or the deletion of only one of the floxed
alleles (Figure 3B; data not shown). We conclude that CD40 plus IL-4 treatment, we performed cell cycle analy-
ses of anti-CD40 plus IL-4-treated (48 hr) splenic B cellsc-Myc-deficient B cells lack ability to undergo full activa-
tion and to proliferate normally in response to mitogen from c-mycfl/fl ; CD19cre mice. These studies showed an
accumulation of G0/G1 phase cells and a reduction ofand lymphokine treatment.
To further analyze the apparent activation defect of S phase cells (Figure 5A). While the cell cycle defects
in these c-mycfl/fl , CD19cre B cell populations appearthe c-Myc-deficient cells, we assayed anti-CD40 plus
IL-4-treated c-mycfl/fl ; CD19cre, c-myc1/fl ; CD19cre, and somewhat less dramatic than those observed for the
c-myc-deleted MEFs, the difference in extent most likelywt splenic B cell populations for expression of early
activation markers including CD69, B7.2, and CD23 (Fig- reflects the more complete c-myc deletion in the MEFs
as compared to the B cell populations, as well as poten-ure 4A). Significantly, we found that this treatment in-
duced expression of all of these markers on both the tial Cre effects on the MEFs (compare Figures 1B and
2C). This view is also supported by the PCR ratios pre-gate R and gate A c-mycfl/fl ; CD19cre B cells to levels
similar to those of activated (gate A) control B cells sented in Figure 3B showing that a minimum of 50% of
the B cell population possesses an intact c-Myc allele(Figure 4A). Anti-CD40 or anti-CD40 plus IL-4 treatment
of normal B cells also is known to induce high levels of at 48 hr post stimulation.
To further verify the impairment in G1 exit, sortedsurface CD95 and CD95L (Rathmell et al., 1995, 1996;
Rothstein et al., 1995). However, we found that anti- mature B cells from c-mycfl/fl ; CD19cre mice were treated
with etoposide, a topoisomerase II inhibitor that inducesCD40 plus IL-4 treatment resulted in only a small in-
Immunity
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Figure 4. Anti-CD40-Treated c-Myc-Deficient
B Cells Express Early Activation Markers but
Not CD95 or CD95L
(A) FACS analysis of surface expression of
CD69, CD23, and B7.2 from anti-CD40 and
interleukin 4 activated B cells (48 hr) from wt,
a heterozygous c-myc1/fl ; CD19cre and a pool
of 3–4 homozygous c-mycfl/fl ; CD19cre mice
(3–4 weeks old). D/D and flox/flox cells were
distinguished using gates R and A, respec-
tively, as in Figure 3A.
(B) FACS analysis of surface expression of
CD95 and CD95L. Cells were activated as (A).
Unstimulated cells were used as a negative
control (shaded area) in all stainings. Results
are representative of three independent ex-
periments. c-myc flox allele (fl).
apoptosis only in cells that are in S phase (Belani et al., analyses to assay for various proteins at a time when
cells would be entering S phase and when the c-Myc1994). Southern blot analysis of DNA from the etoposide-
treated cells showed that proliferating, nondeleted (fl/fl) deleted fraction would be well represented (i.e., 10–15
hr following treatment with anti-CD40 and Il-4). At theseB cells were preferentially killed compared to c-myc-
deficient (D/D) cells, as indicated by the increased ratio times, the c-MycD/D cells generally make up 60%–70%
of the culture, as the c-Mycfl/fl cells have not yet begunof deleted (D) to nondeleted (fl) alleles following etopo-
side treatment (Figure 5B and legend). This resistance to overgrow the cultures (Figure 2C; data not shown).
Notably, the c-mycfl/fl ; CD19cre splenic B cells containedto etoposide-induced death of c-Myc-deficient cells
strongly indicates that these cells are largely nonprolifer- predominantly hypophosphorylated Rb (Lee et al., 1987)
compared to wt controls, in which a significant propor-ative following anti-CD40 and IL-4 treatment. Therefore,
in normal B cells c-Myc is required to facilitate G1 exit, tion of the Rb is in the hyperphosphorylated state (Figure
5C). This finding is consistent with impaired G1 exit ofthereby enabling progression through the S phase fol-
lowing activation. the c-myc-deleted splenic B cell population of the
c-mycfl/fl ; CD19cre mice. In addition, expression of p27To explore potential relationships between c-Myc and
components of the cell cycle machinery governing G1 was elevated in treated c-mycfl/fl ; CD19cre B cells versus
wt B cells (Figure 5C). Finally, Cdk2 and Cyclin D1-exit (Obaya et al., 1999), we employed Western blotting
Conditional Deletion of c-Myc in B Cells
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Figure 5. c-Myc-Deficient Mature B Cells Are
Blocked at G0/G1 Stage of the Cell Cycle
following Anti-CD40 Stimulation
(A) Cell cycle analysis by FACS from sorted
mature B cells from spleen of a wt, a heterozy-
gous c-myc1/fl ; CD19cre, and a pool of 3–4
homozygous c-mycfl/fl ; CD19cre mice. Cells
were activated for 48 hr as in Figure 3A and
stained with propidium iodide (PI).
(B) c-Myc-deficient cells are resistant to etop-
oside treatment. Southern blot of sorted ma-
ture B cells from c-mycfl/fl ; CD19cre mice acti-
vated for 24 hr as in Figure 3A before being
treated with etoposide (10 mM) for an addi-
tional 24 hr. In a second experiment, the ratio
D/flox changed from z30/70 to 70/30 after
etoposide treatment. Quantification was per-
formed with Phosphorimager.
(C) Western blot analysis on B2201 sorted
B cells from c-mycfl/fl ; CD19cre and wt mice
activated as (A) for 10 hr. Rb, retinoblastoma
protein. Actin is used as a loading control for
Rb, p27, and c-Myc immunoblots. a-tubulin
is used as a loading control for p21. Hypo,
hypophosphorylated; and hyper, hyperphos-
phorylated. Experiment shown is representa-
tive of two independent experiments.
(D) CDK2 and Cyclin D1-associated kinase
activities are inhibited in c-Myc-deficient B
cells. The same amounts of protein extract
from activated B cells (10–12 hr) from wt and
c-mycfl/fl ; CD19-Cre mice were immunopre-
cipitated with antibodies to either Cdk2 or
Cyclin D1 and assayed for their ability to
phosphorylate a GST-Rb substrate. The
c-Myc immunoblot for the Cdk2 panel con-
trols for the extent of deletion of c-myc within
the B cell population used for the Cdk2 kinase
assay. As the same extracts were used for
the experiments in (C) and the CyclinD1
assay, the c-Myc immunoblot in (C) serves
as the cMyc deletion control for the Cyclin
D1 panel. Experiments illustrated are repre-
sentative of two or three independent experi-
ments employing different samples. c-myc
flox allele (fl, flox).
associated kinase activities (Matsushime et al., 1992) sion impairs the cellular doubling time and that this im-
pairment is further augmented by deletion of c-myc. Inwere decreased in treated c-mycfl/fl ; CD19cre B cells (Fig-
ure 5D); although expression of Cyclin D1, Cyclin E, contrast, Cre expression appeared to have no major
effect on B cell proliferation in response to treatmentCdk4, and Cdk2 was unaltered (data not shown). More-
over, expression of the cell cycle inhibitor p21Cip1 was with various activating agents. The lack of a Cre effect
in normal B lymphocytes allowed us to clearly demon-moderately reduced in c-mycfl/fl ; CD19cre B cells (Figure
5C). Thus, c-Myc deficiency appears to impair B cell strate a crucial role for c-Myc in B cell proliferative re-
sponses following treatment with activating agents. Theproliferation in part by increasing the level of p27 protein,
likely contributing to the reduction in both Cdk2 and Cyclin c-mycfl/fl mice should now permit further studies of
c-Myc function in various normal cell types and physio-D-associated kinase activities and resulting in mainte-
nance of the pRB hypophosphorylated state. logical settings by circumventing the limitations associ-
ated with the embryonic lethality of c-Myc deficiency in
the germline. At the same time, our studies highlight the
Discussion
need to rule out the possible impact of Cre expression
per se.
The generation of c-mycfl/fl ; CD19cre and c-mycfl/fl mice
via Cre-mediated conditional gene-targeted deletion
strategy has allowed us to further define the role of The c-myc Gene Is Required for MEF Proliferation
We find that c-Myc-deficient MEFs are impaired in theirc-Myc in normal cells generated in vivo. In addition,
these studies have revealed unanticipated cell-type- ability to proliferate beyond effects attributable to Cre
expression. Further, these defects correlate with upreg-specific effects of Cre expression with respect to cell
proliferation. In MEFs, we have shown that Cre expres- ulation of the cell cycle inhibitor p27; the potential impli-
Immunity
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cations of p27 upregulation are discussed in more detail upon treatment with anti-CD40 and IL-4, c-Myc-defi-
cient B cells upregulated early activation markers butbelow. However, we do note that the c-Myc-deficient
MEFs are capable of proliferating at a very slow rate. showed a forward/side-scatter profile typical of nonacti-
vated cells. In addition, these mutant B cells were se-The proliferation defect of c-Myc-deficient MEFs is con-
sistent with previous findings that sequential deletion verely impaired in ability to proliferate, and they showed
increased levels of the cell cycle inhibitor p27 (relativeof the c-myc genes in RAT1a fibroblasts resulted in a
prolonged cellular doubling time (Mateyak et al., 1997). to similarly treated wt cells). In fibroblasts, c-Myc over-
expression prevents inactivation of cyclin E/CDK2 asHowever, the increased doubling time of c-Myc-defi-
cient MEFs (z200 hr versus 20 hr for wt MEFs) is much well as dephosphorylation of Rb, and allows continuous
cell proliferation in the presence of enforced p27 expres-greater than that measured for c-Myc-deficient RAT1a
cells (z50 hr versus 20 hr for wt RAT1a cells). Moreover, sion by presumably sequestering p27 away from cyclin
E/CDK2 complexes (Vlach et al., 1996). In B cell lympho-acute deletion of c-myc in MEFs resulted in arrest in the
G0/G1 phase of the cell cycle and no increase in G2/M. mas, increased expression of p27 protein is associated
with growth arrest upon IgM receptor activation (Ezhev-In contrast, c-myc-deficient RAT1a cells appear to ex-
hibit prolonged G1 and G2 phases (Mateyak et al., 1997). sky et al., 1996). Our data indicate that the presence of
c-Myc in B lymphocytes can also lead to decreasedOne possible explanation for these apparent differences
might be cell- or species-specific differences. Another levels of p27, suggesting an additional regulatory mech-
anism of p27 by c-Myc. The ability of c-Myc to promotemight be related to the different methods used to gener-
ate the c-Myc-deficient fibroblasts (Cre deletion versus ubiquitin-dependent degradation of p27 in MEFs (O’Hagan
et al., 2000) accounts at least in part for this regulation.sequential targeting); for example, sequential targeting
could theoretically allow the selection of growth-com- In addition, c-Myc acts via Inr elements to repress gene
expression, and the presence of an Inr element in thepensating mutations (Mateyak et al., 1997), whereas the
effect of Cre expression might exacerbate the effect of p27 promoter (Li et al., 1994; Mateyak et al., 1999), in
combination with our in vivo results, indicates that directc-myc deletion upon proliferation.
The inability of ectopic c-Myc to fully rescue prolifera- repression of p27 by c-Myc may also be a physiologi-
cally relevant mechanism.tion of c-Myc null MEFs may be due to the Myc-indepen-
dent inhibition effected by expression of Cre, or the
nonphysiological level at which retrovirally transduced c-Myc Null Cells Express Low Levels of CD95
c-Myc is expressed. In any case, the ability of c-Myc- and CD95L following B Cell Activation
deficient MEFs to proliferate at very low levels suggests Our findings demonstrate that mitogen-stimulated,
either that c-Myc is not absolutely required for prolifera- c-Myc-deficient splenic B lymphocytes express very low
tion and/or that there are factors that are partially redun- levels of surface CD95 and CD95L as compared to
dant for this aspect of c-Myc function in MEFs. However, treated control cells. However, our findings cannot dis-
the G0/G1 arrest observed upon acute deletion of tinguish definitively as to whether the decreased CD95/
c-myc in MEFs, the severely impaired ability of these CD95L expression results from a direct role for c-Myc
MEFs to proliferate, and the ability of ectopic Myc ex- in regulating expression of these proteins or is second-
pression to significantly restore the growth potential of ary to a defect in B cell activation. In the context of
c-Myc null MEFs lead us to conclude that c-Myc is a a secondary effect, high-level CD95/CD95L expression
key regulator of the G1/S transition in MEFs. would be a downstream event in the context of B cell
The inhibitory effect of Cre on proliferation of wt MEFs activation. However, anti-CD40 plus IL-4-treated, c-Myc-
appears to be effected through a Myc-independent deficient B cells express early activation markers, indi-
mechanism since expression of Cre does not affect the cating that they are receptive to activation signals. Other
level of p27Kip1 protein. However, the specific mechanism studies have shown that CD95/CD95L is induced in nor-
is unclear at this time. In any case, our findings demon- mal B cells following treatment with anti-CD40, leading
strate that it is important to control for Cre effects in experi- to susceptibility to apoptosis via the CD95 pathway
ments utilizing Cre-mediated gene deletion. Moreover, dif- (Rathmell et al., 1995, 1996; Rothstein et al., 1995). In T
ferent forms of Cre-recombinase (e.g., Cre-ER), different cell hybridomas, it has been suggested that CD95 and
levels of Cre expression, or the cell type analyzed (e.g., CD95L expression is directly regulated by c-Myc (Gen-
MEFs versus B lymphocytes) may lead to greater or estier et al., 1999). Our current findings would be consis-
lesser extents of Cre effects on proliferation. Such is- tent with a similar mode of CD95/CD95L regulation via
sues remain to be resolved. c-Myc in normal B cells.
Experimental ProceduresThe c-myc Gene Is Required for Normal B Cell
Activation and Proliferation
Generation of c-mycfl/fl Mice
The outgrowth of non-c-myc-deleted cells from mito- A loxP site with a new EcoRI site was cloned into the unique DraIII
gen-stimulated nondeleted/deleted mixed B lympho- site between exon 1 and 2 of the c-myc gene (fl neo allele). In brief,
TC1 ES cells (129, kindly provided by P. Leder) were transfected bycyte cultures could result from either decreased prolifer-
electroporation using conventional targeting methods (Thomas andation of c-myc-deleted B cells, increased cell death of
Capecchi, 1987; Gu et al., 1993). Subsequently, heterozygous mu-c-myc-deleted B cells, or both. While the presence of
tant (c-mycfl neo/1) ES cells were transiently transfected with a creproliferating, non-c-myc-deleted B cells in the culture
expressing vector (PMCcre) to remove the selectable marker (Neo)
of c-mycfl/fl ; CD19cre mice prevented a direct assessment to avoid any interference with expression of c-myc gene. Heterozy-
of cell death, we were able to clearly show that c-myc- gous ES clones (c-mycfl/1) were injected into C57Bl/6 blastocysts
to generate germline mutant mice.deleted cells had a severe proliferation defect. Thus,
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Generation of c-myc-Deficient Mouse Embryonic thank L. Torroja and X. Mao for their input. I. M. A. was a recipient of
a fellowship from the Spanish Ministry of Education and is currently aFibroblasts (D/D MEFs)
Fibroblasts were generated from 13.5 day c-mycfl/fl embryos and Howard Hughes Medical Institute Associate. R. C. O. is a recipient
of a fellowship from the Jane Coffin Childs Memorial Fund for Medi-grown in 10 cm dishes until 70%–80% confluent. Subsequently,
to delete c-myc gene a retroviral based vector expressing green cal Research. This work was supported by NIH grants CA61009
(to B. A. M.), HD28317 and EY09300 (to R. A. D.), and AI35714fluorescent protein fused to Cre protein (kindly provided by H. Hock
and C. Klein) was used to infect c-mycfl/fl fibroblasts (1 3 107 pfu/ (to F. W. A.) and a Max Planck Research Award to K. R. R. A. D. is
an American Cancer Society Research Professor. F. W. A. is anper 10 cm dish). A retrovirus expressing GFP only was used as a
control. After 48 hr in culture, GFP-positive cells were sorted by Investigator and F. G. an Associate of the Howard Hughes Medical
Institute.FACS. After cell sorting, GFP1 fibroblasts were cultured in DMEN
(15% FCS). For growth curves, MEFs were seeded at 2 3 105 per
10 cm plate in duplicate and counted at the times indicated in Figure Received September 13, 2000; revised December 11, 2000.
1C. Cell cycle profiles were obtained by FACS analysis of PI-stained
cells. Proliferation rates were measured using a WST-1 cleavage
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